ARS Pharmaceuticals, Inc.

NasdaqGM SPRY

ARS Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

ARS Pharmaceuticals, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).
  • ARS Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -392.00 K, a 37.08% change year over year.
  • ARS Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -623.00 K.
Key data
Date Capital Expenditure Free Cash Flow Depreciation And Amortization Deferred Income Tax
Market news
Loading...
SV Wall Street
NasdaqGM: SPRY

ARS Pharmaceuticals, Inc.

CEO Mr. Richard Lowenthal M.B.A., M.S., MSMSEL
IPO Date Dec. 4, 2020
Location United States
Headquarters 3525 Del Mar Heights Road
Employees 24
Sector Healthcare
Industries
Description

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

Similar companies

PALI

Palisade Bio, Inc.

USD 1.36

-4.90%

WVE

Wave Life Sciences Ltd.

USD 11.57

-4.06%

ZURA

Zura Bio Limited

USD 1.88

6.82%

DRMA

Dermata Therapeutics, Inc.

USD 1.23

2.50%

CUE

Cue Biopharma, Inc.

USD 1.45

6.62%

ANNX

Annexon, Inc.

USD 3.84

-4.95%

IMMX

Immix Biopharma, Inc.

USD 1.94

-1.52%

TCRX

TScan Therapeutics, Inc.

USD 2.57

-0.39%

StockViz Staff

February 3, 2025

Any question? Send us an email